Eco Animal Health (GB:EAH) has released an update.
ECO Animal Health Group reports a robust financial year ending March 2024, with a 5% increase in sales to £89.4m and an 11% rise in constant currency revenue, despite a slight decline in gross margin. The company has seen significant growth in North America and Latin America, and it remains committed to its R&D investments, particularly with the anticipated launch of its poultry vaccine ECOVAXXIN® in 2025. ECO’s strong balance sheet is supported by an increase in adjusted EBITDA to £8.0m and a net cash position of £22.4m.
For further insights into GB:EAH stock, check out TipRanks’ Stock Analysis page.
